A
Alexandra Holmström
Researcher at Stanford University
Publications - 14
Citations - 1094
Alexandra Holmström is an academic researcher from Stanford University. The author has contributed to research in topics: Induced pluripotent stem cell & Heart failure. The author has an hindex of 8, co-authored 14 publications receiving 876 citations. Previous affiliations of Alexandra Holmström include Sahlgrenska University Hospital & University of Gothenburg.
Papers
More filters
Journal ArticleDOI
Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity
Paul W. Burridge,Yong Fuga Li,Elena Matsa,Haodi Wu,Sang-Ging Ong,Arun Sharma,Alexandra Holmström,Alex C.Y. Chang,Michael Coronado,Antje D. Ebert,Joshua W. Knowles,Melinda L. Telli,Ronald M. Witteles,Helen M. Blau,Daniel Bernstein,Russ B. Altman,Joseph C. Wu +16 more
TL;DR: It is demonstrated that patient-specific human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) can recapitulate the predilection to doxorubicin-induced cardiotoxicity of individual patients at the cellular level.
Journal ArticleDOI
High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells
Arun Sharma,Paul W. Burridge,Paul W. Burridge,Wesley L. McKeithan,Wesley L. McKeithan,Ricardo Serrano,Praveen K. Shukla,Nazish Sayed,Jared M. Churko,Tomoya Kitani,Haodi Wu,Alexandra Holmström,Elena Matsa,Yuan Zhang,Anusha Kumar,Alice C. Fan,Juan C. del Álamo,Sean M. Wu,Javid Moslehi,Mark Mercola,Mark Mercola,Joseph C. Wu +21 more
TL;DR: In this article, the authors used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), generated from 11 healthy individuals and 2 patients receiving cancer treatment, to screen U.S. Food and Drug Administration-approved TKIs for cardiotoxicities by measuring alterations in Cardiomyocyte viability, contractility, electrophysiology, calcium handling, and signaling.
Journal ArticleDOI
Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells.
Paul W. Burridge,Paul W. Burridge,Alexandra Holmström,Alexandra Holmström,Joseph C. Wu,Joseph C. Wu +5 more
TL;DR: The latest, cost‐effective and efficient methodology for the culture of hPS cells in the pluripotent state using a modified variant of chemically defined E8 medium is described and exact guidelines for cell handling under these conditions are provided, including non‐enzymatic EDTA passaging.
Journal ArticleDOI
Comparison of Non-human Primate versus Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Treatment of Myocardial Infarction.
Xin Zhao,Haodong Chen,Haodong Chen,Dan Xiao,Dan Xiao,Huaxiao Yang,Huaxiao Yang,Ilanit Itzhaki,Ilanit Itzhaki,Xulei Qin,Xulei Qin,Tony Chour,Tony Chour,Aitor Aguirre,Kim A. Lehmann,Youngkyun Kim,Youngkyun Kim,Praveen K. Shukla,Praveen K. Shukla,Alexandra Holmström,Alexandra Holmström,Joe Z. Zhang,Joe Z. Zhang,Yan Zhuge,Yan Zhuge,Babacar C. Ndoye,Babacar C. Ndoye,Ming-Tao Zhao,Ming-Tao Zhao,Evgenios Neofytou,Evgenios Neofytou,Wolfram-Hubertus Zimmermann,Mohit Jain,Joseph C. Wu,Joseph C. Wu +34 more
TL;DR: Both NHP and human iPSC-CMs confer similar cardioprotection in a rodent myocardial infarction model through relatively similar mechanisms via promotion of cell survival, angiogenesis, and inhibition of hypertrophy and fibrosis.
Journal ArticleDOI
Red blood cell distribution width and its relation to cardiac function and biomarkers in a prospective hospital cohort referred for echocardiography
Alexandra Holmström,Runa Sigurjonsdottir,Ola Hammarsten,Dan Gustafsson,Max Petzold,Michael Fu +5 more
TL;DR: In patients referred for echocardiography because of suspected HF, RDW levels were higher in patients with SHF and HFNEF, and NT-proBNP levels were independently linked with elevated RDW.